Coya Therapeutics (COYA) Competitors $5.24 +0.08 (+1.55%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends COYA vs. NGNE, PROC, DSGN, VYGR, CTNM, BTMD, SLRN, KMDA, CGC, and ETONShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Neurogene (NGNE), Procaps Group (PROC), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), biote (BTMD), Acelyrin (SLRN), Kamada (KMDA), Canopy Growth (CGC), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Neurogene Procaps Group Design Therapeutics Voyager Therapeutics Contineum Therapeutics biote Acelyrin Kamada Canopy Growth Eton Pharmaceuticals Neurogene (NASDAQ:NGNE) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Does the media prefer NGNE or COYA? In the previous week, Coya Therapeutics had 2 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Coya Therapeutics and 0 mentions for Neurogene. Coya Therapeutics' average media sentiment score of 0.30 beat Neurogene's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neurogene Neutral Coya Therapeutics Neutral Which has more risk and volatility, NGNE or COYA? Neurogene has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Is NGNE or COYA more profitable? Coya Therapeutics' return on equity of -31.63% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -32.81% -27.96% Coya Therapeutics N/A -31.63%-27.76% Do analysts recommend NGNE or COYA? Neurogene presently has a consensus price target of $60.83, indicating a potential upside of 168.70%. Coya Therapeutics has a consensus price target of $16.25, indicating a potential upside of 210.11%. Given Coya Therapeutics' higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in NGNE or COYA? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 9.9% of Neurogene shares are owned by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, NGNE or COYA? Coya Therapeutics has higher revenue and earnings than Neurogene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$925K363.59-$36.32MN/AN/ACoya Therapeutics$9.55M9.16-$7.99M-$0.65-8.06 Does the MarketBeat Community believe in NGNE or COYA? Neurogene received 10 more outperform votes than Coya Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Neurogene an outperform vote while only 94.12% of users gave Coya Therapeutics an outperform vote. CompanyUnderperformOutperformNeurogeneOutperform Votes26100.00% Underperform VotesNo VotesCoya TherapeuticsOutperform Votes1694.12% Underperform Votes15.88% SummaryNeurogene and Coya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.55M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-8.0610.5990.0517.18Price / Sales9.16195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book2.125.094.784.78Net Income-$7.99M$151.83M$120.31M$225.60M7 Day Performance-11.04%-2.13%-1.92%-1.23%1 Month Performance-13.82%-3.10%11.51%3.36%1 Year Performance-23.05%11.54%30.61%16.60% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.1484 of 5 stars$5.24+1.6%$16.25+210.1%-23.7%$87.55M$9.55M-8.066Analyst ForecastGap UpNGNENeurogene3.7337 of 5 stars$25.13+6.9%$60.83+142.1%N/A$373.31M$925,000.000.0090PROCProcaps Group0.8826 of 5 stars$3.25+34.9%N/A-20.3%$366.67M$414.10M5.105,500News CoverageHigh Trading VolumeDSGNDesign Therapeutics0.9221 of 5 stars$6.29+12.3%$7.00+11.3%+143.2%$356.15MN/A-7.1840News CoveragePositive NewsVYGRVoyager Therapeutics4.6087 of 5 stars$6.48+3.3%$17.00+162.3%-27.6%$354.00M$250.01M8.83100CTNMContineum Therapeutics1.9558 of 5 stars$13.66-2.6%$29.25+114.1%N/A$352.13M$50M0.0031News CoverageHigh Trading VolumeBTMDbiote3.0893 of 5 stars$6.39+0.3%$9.11+42.6%+20.8%$347.21M$193.06M24.77194Positive NewsGap UpSLRNAcelyrin2.7848 of 5 stars$3.37+4.3%$11.75+248.7%-55.8%$338.11MN/A-1.31135KMDAKamada3.8909 of 5 stars$5.80-1.2%$14.50+150.0%-1.2%$333.38M$158.38M20.96360Positive NewsCGCCanopy Growth2.436 of 5 stars$3.04-2.3%$3.50+15.1%-41.0%$331.18M$220.27M-0.621,029Analyst RevisionNews CoverageETONEton Pharmaceuticals2.1328 of 5 stars$12.74+3.2%$15.00+17.7%+176.9%$329.20M$31.64M-56.1420High Trading Volume Related Companies and Tools Related Companies Neurogene Competitors Procaps Group Competitors Design Therapeutics Competitors Voyager Therapeutics Competitors Contineum Therapeutics Competitors biote Competitors Acelyrin Competitors Kamada Competitors Canopy Growth Competitors Eton Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COYA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COYA Stock Alerts